Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Conivaptan - Cumberland Pharmaceuticals

Next Previous
X
Search
Drug Profile

Conivaptan - Cumberland Pharmaceuticals

Alternative Names: CI-1025; Conivaptan hydrochloride; Vaprisol; YM-087

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Alliance Healthcare; Cumberland Pharmaceuticals; DB Pharm Korea; Piramal Critical Care
  • Class Benzazepines; Small molecules
  • Mechanism of Action Vasopressin 1 receptor antagonists; Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyponatraemia
  • Discontinued Heart failure

Most Recent Events

  • 09 Jul 2019 Discontinued - Phase-III for Hyponatraemia in South Africa (IV)
  • 31 Dec 2018 Cumberland Pharmaceuticals owns several US and international patents covering conivaptan
  • 04 Apr 2016 Cumberland Pharmaceuticals and Clinigen enter into a licensing agreement to develop Vaprisol® (Cumberland Pharmaceuticals, Form 10-K, March 2016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top